Fig. 7
From: Antibiotic-induced gut microbiota dysbiosis has a functional impact on purine metabolism
Lactobacillus sp. ASF360 decreases hyperuricemia. (a) Morphology of Lactobacillus sp. ASF360 on Columbia blood agar. (b) The morphology of Lactobacillus sp. ASF360 under electron microscope. (c) Lactobacillus sp. ASF360 was identified by 16 S rRNA gene sequences. (d) The sequence identity of Lactobacillus sp. ASF360 and Lactobacillus vaginalis by BLAST. (e) The PPI analysis of Lactobacillus sp. ASF360. (f) The UA levels in the supernatant of Lactobacillus sp. ASF360 and NCM-460 co-culture over 6 h. (g) The UA concentration in the supernatant of inosine treated Lactobacillus sp. ASF360. These results are expressed as mean ± SEM. **P < 0.01, vs. control group. (h) The diagram of Lactobacillus sp. ASF360 intervention on the hyperuricemia mouse. (i) The initial UA before Lactobacillus sp. ASF360 treatment. (j) The UA level after Lactobacillus sp. ASF360 treatment for 20 days. These results are expressed as mean ± SEM.*P < 0.05, **P < 0.01, ***P < 0.001vs. M group. NC, control; M, hyperuricemia model mouse; M-lac.sp.ASF360, Lactobacillus sp. ASF360-fed hyperuricemia model mouse; XO, xanthine oxidase; UA, uric acid